Articles On Prescient Therapeutics (ASX:PTX)

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

The new appointments will support Prescient’s ongoing and novel development of its Omnicar CAR-T therapy. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has bolstered its advisory board after announcing the appointments of...

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary OmniCAR platform after unveiling two high-profile additions to its scientific advisory board. In a statement to the m...

Highlights Despite pandemic, few ASX companies have delivered outstanding returns. LTR, ACB, PTX, NVX and IMU have gained over 300% so far. Few ASX listed stocks have given outstanding returns despite the pandemic challenges. Let’...

Clinical-stage oncology company Prescient Therapeutics (PTX) eyes several milestones across its anti-cancer programs after a busy September quarter Prescient says “positive” results from testing of its OmniCAR platform have de-risked the p...

Prescient Therapeutics (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell and Gene Meeting in the US.

Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting the attention of leading global therapy decision makers. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) will pr...

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its OmniCAR cell therapy technology in killing multiple cancer cells. The company is presenting this pre-clinical da...

Prescient Therapeutics (PTX) will present new results this week for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California The conference brings together senior executives and decision makers on therapies including cell ther...

Highlights The ASX 200 was up 0.25% or 18.7 points to 7,361.3 at the open. Seven out of the 11 sectors were trading higher with the Metals and Mining sector leading with a 0.3% gain Limeade, Inc received a notice of contract terminati...

The S&P/ASX 200 index (ASX: XJO) has started the week in the red and is currently down 2% to 7,252.6 points. Whereas the S&P/ASX 200 Health Care index (XHJ) is also around 1% in the red today, one ASX Healthcare share is outpacing...

The Prescient Therapeutics Ltd (ASX: PTX) share price has gained a further 5% to trade at 23 cents on Thursday afternoon. Prescient shares have been on the move over this past week and have climbed 28% into the green over this time. What...

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Steven Yatomi-Clarke, the CEO & Managing Director of Prescient Therapeutics (PTX), speaks to Peter Switzer.

Highlights  ASX-listed healthcare companies rarely fail to bring joy to the market participants, with a few of them providing outstanding returns in the last couple of months. Rhinomed, IDT Australia, and Prescient lead the way with ou...

ShareCafeA diversified portfolio of cancer treatment medicines Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers. A diversified portfol...

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Steven Yatomi-Clarke, CEO and managing...

The appointment gives PTX a world-leading development team in the race to find solutions for next-generation CAR-T cancer therapies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced a major new staff hire this...

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to its scientific advisory board. Professor O’Rourke has considerable expertise in glioblastoma multiforme (GB...

Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted ther...

Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple cancer programs, with work to follow on from what managing director Steven Yatomi-Clarke describes as “tremendous...

The Prescient Therapeutics Ltd (ASX: PTX) share price is off to the races, up 8% to 19.5 cents in early afternoon trade. Prescient is a clinical-stage oncology company focused on developing personalised treatments for cancer. Below, we tak...

Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an early clinical trial – and seemed to benefit two patients with aggressive, hard-to-treat lymphoma. Prescient says it is encoura...

The Prescient Therapeutics Ltd (ASX: PTX) share price is having a lacklustre day, despite a positive readout on its PTX-100 trial. Prescient shares dipped into the red in morning trade. However, at the time of writing they are exchanging...

The Prescient Therapeutics Ltd (ASX: PTX) share price is soaring today, despite the company not releasing any news. The last time we heard price-sensitive news from the biotechnology company was on 5 July. Right now, the Prescient Therapeu...

Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news its cancer treatment drug, OmniCAR, has been substantially de-risked. After reaching a multi-year high of 26.5 cents this morning, the...

The results significantly de-risk the project as PTX continues development of its OmniCAR platform.  As it builds out its OmniCAR cancer treatment platform, clinical stage oncology company Prescient Therapeutics (ASX:PTX) has updated invest...

Wall Street at fresh record highs All three major US benchmarks closed on Friday at new record highs, with intraday gains led by the tech-focused Nasdaq which was 0.81%. US stocks were bolstered by monthly jobs data which showed the unemplo...

Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a sobering reminder of the dangers involved in cell therapy. The patients reportedly died from immune effector...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

The company will now proceed to its next phase of research at the world-leading Peter Mac cancer research centre. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced another crucial step forward in the development...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising the OmniCAR platform.

The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements.

The deal provides the ideal platform for Prescient to develop its OmniCAR product suite as part of broader CAR-T cancer treatment pathways. Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this m...

With the number of days left to file March quarterly reports running a little short this month, it is no surprise that the ASX has been flooded with companies racing to beat the deadline. We begin this roundup with Marenica Energy (ASX:MEY)...

Wall Street wobbles on tax hike All three major indices in the US fell overnight, after a report saying that the Biden administration may increase the capital gains tax on wealthy individuals. The Dow Jones fell 0.94%, the S&P500 was do...

Our summary of Prescient Therapeutics Ltd's recent announcement What has happened? Prescient Therapeutics (PTX:ASX) announced their second-quarter activities and cashflow report which covered their financials, the PTX-100 and PTX-200 clinic...

Special Report: Australian biotech company Prescient Therapeutics (ASX:PTX) has announced what’s next for its next-generation gene therapy technology for fighting ... Read More The post Prescient Therapeutics chooses three cancer programs f...

Summary Prescient Therapeutics announced three internal development programs related to unique OmniCAR capabilities. Each of the OmniCAR development programs signifies a considerable market opportunity for the oncology company. Presci...

Our summary of Prescient Therapeutics Ltd's recent announcement What's happened? Prescient Therapeutics (ASX:PTX) today announced three new internal development programs for OmniCAR, it's next-generation CAR-T cancer therapy platform, whic...

Prescient Therapeutics CEO Steven Yatomi-Clarke speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

Summary Prescient Therapeutics has appointed Professor H. Miles Prince to its Scientific Advisory Board. Professor Prince holds significant experience in several other areas of cancer therapies and drug development. He has pioneered t...

Summary Last 12 months have been fruitful for Prescient Therapeutics despite the challenges and uncertainties amid the COVID-19. The Company achieved its objectives for targeted as well as cell therapies during the period. A truly tra...

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treat...

Summary Prescient ended the September 2020 quarter with a cash balance of almost A$18.6 million following the successful capital raising in August 2020. During the quarter, two assets of PTX were selected for priority antiviral COVID-19...

Summary Supported by an international leadership team with extensive expertise in cancer therapy, Prescient has developed a robust product pipeline, comprising personalised cancer treatments. Prescient’s drug pipeline comprises CAR-T an...

Prescient Therapeutics (ASX:PTX) has announced that it has received commitments to raise over $7 million before costs by way of a share placement to professional and sophisticated investors.